BG-9928 (Biogen Idec).

Article Details

Citation
Copy to clipboard

Doggrell SA

BG-9928 (Biogen Idec).

Curr Opin Investig Drugs. 2005 Sep;6(9):962-8.

PubMed ID
16187697 [ View in PubMed
]
Abstract

Biogen Idec, under license from CV Therapeutics, is developing BG-9928, a selective oral adenosine A, receptor antagonist, for the potential treatment of congestive heart failure. By January 2003, phase II trials of BG-9928 were ongoing.

DrugBank Data that Cites this Article

Drugs